Cem Akin
Immunology and Microbiology · University of Michigan
Publications
402
Citations
19,385
Est. group size
~2
Recurring co-author estimate
Active years
39
Publishing since 1988
Typically publishes in teams of ~10 · 27% small-team papers (≤3 authors) · across 49 venues
- Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
Journal of Allergy and Clinical Immunology · 2026
- Mastocytosis
Nature Reviews Disease Primers · 2025
- Systemic Mastocytosis: Current Status and Challenges in 2024
Blood Advances · 2025
- Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosis
The Journal of Allergy and Clinical Immunology In Practice · 2025
- How we treat mast cell activation syndrome
Annals of Allergy Asthma & Immunology · 2025
- Management of indolent mastocytosis and mast cell activation syndrome
Annals of Allergy Asthma & Immunology · 2025
- Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation
Journal of Allergy and Clinical Immunology · 2025
- Avapritinib and Bone Health in Indolent Systemic Mastocytosis: Learnings from the PIONEER Trial
Journal of Allergy and Clinical Immunology · 2025
- MPN-573: Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis Patients and Establishing Content Validity
Clinical Lymphoma Myeloma & Leukemia · 2025
- Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study
Blood · 2025
- Evaluation of Baseline Apolipoprotein A1 Level in Anaphylaxis and Mastocytosis
Journal of Allergy and Clinical Immunology · 2025
- Comprehensive Analysis of Immunoglobulin E Levels in Healthy Donors and Patients With Indolent Systemic Mastocytosis Enrolled on the PIONEER Trial of Avapritinib
Journal of Allergy and Clinical Immunology · 2025
- Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib
Journal of Allergy and Clinical Immunology · 2025
- Baseline Serum Tryptase Correlation with Severe Reactions to Allergen and Venom Immunotherapy
Journal of Allergy and Clinical Immunology · 2025
- Responses to Avapritinib in Patients Without Detectable KIT Mutations by ddPCR in Peripheral Blood Highlight Diagnostic Challenges and Opportunities in Indolent Systemic Mastocytosis
Journal of Allergy and Clinical Immunology · 2025
- Journal of Allergy and Clinical Immunology×51
- The Journal of Allergy and Clinical Immunology In Practice×35
- Annals of Allergy Asthma & Immunology×14
- Blood×9
- Immunology and Allergy Clinics of North America×7
- Varsha Ganesan
Immunology and Microbiology · University of Michigan
- Cem Akın
Immunology and Microbiology · University of Michigan
- HM Kim
Immunology and Microbiology · University of Michigan
- Dilawar Khokhar
Medicine · University of Michigan
- Masako Toda
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile